CN101203605B - 革兰氏阴性菌的lps的脱酰基化 - Google Patents

革兰氏阴性菌的lps的脱酰基化 Download PDF

Info

Publication number
CN101203605B
CN101203605B CN200580048420.6A CN200580048420A CN101203605B CN 101203605 B CN101203605 B CN 101203605B CN 200580048420 A CN200580048420 A CN 200580048420A CN 101203605 B CN101203605 B CN 101203605B
Authority
CN
China
Prior art keywords
lps
pagl
lipid
bordetella
gram
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200580048420.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN101203605A (zh
Inventor
J·P·M·托马森
P·A·范德莱
J·J·G·戈尔特森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Government of Netherlands
Original Assignee
Government of Netherlands
NVI Nederlands Vaccininstituut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government of Netherlands, NVI Nederlands Vaccininstituut filed Critical Government of Netherlands
Publication of CN101203605A publication Critical patent/CN101203605A/zh
Application granted granted Critical
Publication of CN101203605B publication Critical patent/CN101203605B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN200580048420.6A 2004-12-17 2005-12-16 革兰氏阴性菌的lps的脱酰基化 Expired - Fee Related CN101203605B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04078445 2004-12-17
EP04078445.6 2004-12-17
PCT/NL2005/050081 WO2006065139A2 (en) 2004-12-17 2005-12-16 Deacylation of lps in gram negative bacteria

Publications (2)

Publication Number Publication Date
CN101203605A CN101203605A (zh) 2008-06-18
CN101203605B true CN101203605B (zh) 2016-01-27

Family

ID=34928754

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200580048420.6A Expired - Fee Related CN101203605B (zh) 2004-12-17 2005-12-16 革兰氏阴性菌的lps的脱酰基化

Country Status (15)

Country Link
US (1) US8048433B2 (enExample)
EP (1) EP1828378B1 (enExample)
JP (1) JP5378685B2 (enExample)
CN (1) CN101203605B (enExample)
AU (1) AU2005317304B2 (enExample)
BR (1) BRPI0519923A8 (enExample)
CA (1) CA2590906C (enExample)
DK (1) DK1828378T3 (enExample)
ES (1) ES2493440T3 (enExample)
MX (1) MX2007007288A (enExample)
NO (1) NO340331B1 (enExample)
NZ (1) NZ555889A (enExample)
PL (1) PL1828378T3 (enExample)
PT (1) PT1828378E (enExample)
WO (1) WO2006065139A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101801997B (zh) * 2007-03-26 2016-06-01 由卫生福利和体育大臣代表的荷兰王国 基于lps糖基转移酶突变体的改进的抗百日咳博德特氏菌疫苗
SG11201500573RA (en) 2012-08-06 2015-02-27 Glaxosmithkline Biolog Sa Method for eliciting in infants an immune response against rsv and b. pertussis
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
WO2014196887A1 (ru) 2013-06-04 2014-12-11 Aparin Petr Gennadievich Модифицированный липополисахарид эндотоксичных бактерий (варианты), комбинация модифицированных липополисахаридов (варианты) и включающие их вакцина (варианты) и фармацевтическая композиция (варианты)
US11052142B2 (en) 2013-06-04 2021-07-06 Petr G. Aparin Modified endotoxic bacteria lipopolysaccharide (variants), combination of modified lipopolysaccharides (variants) and, containing same, a vaccine (variants) and a pharmaceutical composition (variants)
SG11201600709TA (en) 2013-08-05 2016-02-26 Glaxosmithkline Biolog Sa Combination immunogenic compositions
WO2015179270A2 (en) 2014-05-19 2015-11-26 Board Of Regents, The University Of Texas System Combinatorial platform for the display of surface adjuvants and antigens
CN104388368B (zh) * 2014-10-30 2017-02-15 四川农业大学 一株低内毒素大肠杆菌原核表达工程菌突变株及构建方法
EP3408274A1 (en) * 2016-01-28 2018-12-05 De Staat der Nederlanden, vert. door de minister Van VWS, Ministerie van Volksgezondheid, Welzijn en Sport Modified tetra-acylated neisserial lps
CN105567620B (zh) * 2016-01-29 2019-03-19 江南大学 一株产减毒类脂A的Cronobacter sakazakii突变株及其应用
CN105695540A (zh) * 2016-03-18 2016-06-22 辽宁成大生物股份有限公司 一种革兰氏阴性菌胞壁抗原的制备方法
CA3055757A1 (en) * 2017-03-13 2018-09-20 De Staat Der Nederlanden, Vert. Door De Minister Van Vws, Ministerie Van Volksgezondheid, Welzijn En Sport Bordetella vaccines comprising lps with reduced reactogenicity
WO2018213242A1 (en) * 2017-05-15 2018-11-22 University Of Maryland, Baltimore Live salmonella typhi vectors engineered to express heterologous outer membrane protein antigens and methods of use thereof
KR102822764B1 (ko) * 2017-12-04 2025-06-19 인트라백 비.브이. 외막 소포의 생성을 위한 개선된 방법
US20230183656A1 (en) * 2020-05-14 2023-06-15 Merck Patent Gmbh Methods and compositions for purifying adeno associated virus particles or adenoviruses
US20250263447A1 (en) 2020-09-04 2025-08-21 Intravacc B.V. Ompa mutations enhance omv production in bordetella pertussis
EP4169513A1 (en) 2021-10-19 2023-04-26 GlaxoSmithKline Biologicals S.A. Adjuvant composition comprising sting agonists

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1033072A (zh) * 1987-09-04 1989-05-24 安姆根有限公司 重组dna产生的博德特氏菌毒素亚基类似物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH650681A5 (en) * 1981-08-14 1985-08-15 Dso Pharmachim Whooping cough vaccine
EP0484621A3 (en) * 1990-07-11 1992-08-26 American Cyanamid Company Efficacious vaccines against bordetella pertussis comprising a combination of individually purified pertussis antigens
DE69333467T2 (de) * 1992-08-18 2005-01-20 Dimminaco Ag Bordetella bronchiseptica impfstoff
PT826001E (pt) * 1995-05-04 2002-12-31 Aventis Pasteur Vacinas acelulares contra a tosse convulsa e metodos para a sua preparacao
US6887483B2 (en) 1995-12-01 2005-05-03 University Of Iowa Research Foundation Non-toxic mutants of pathogenic gram-negative bacteria
AU743114B2 (en) * 1997-04-01 2002-01-17 Corixa Corporation Aqueous immunologic adjuvant compositions of monophosphoryl lipid A
CA2264970A1 (en) * 1998-03-10 1999-09-10 American Cyanamid Company Antigenic conjugates of conserved lipolysaccharides of gram negative bacteria
PT1127137E (pt) * 1998-11-03 2007-12-28 Staat Nl Verteg Door Min Welzi Lps com toxicidade reduzida a partir de bactérias gramnegativas modificadas geneticamente
US6531131B1 (en) * 1999-08-10 2003-03-11 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for Neisseria meningitidis
AU2002307448A1 (en) * 2001-04-20 2002-11-05 President And Fellows Of Harvard College Methods and compositions for the modulation of biofilm formation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1033072A (zh) * 1987-09-04 1989-05-24 安姆根有限公司 重组dna产生的博德特氏菌毒素亚基类似物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Caroff M at al.Structural variability and originality of the Bordetella endotoxins.《JOURNAL OF ENDOTOXIN RESEARCH》.2001,第7卷(第1期),63-68. *
Parkhill Julian et al.Comparative analysis of the genome sequence of Bordetella pertussis,Bordetella parapertussis and bordetella bronchiseptica.《NATURE GENETICS》.2003,第35卷(第1期),32-40. *

Also Published As

Publication number Publication date
JP5378685B2 (ja) 2013-12-25
WO2006065139A3 (en) 2006-10-19
CA2590906A1 (en) 2006-06-22
AU2005317304B2 (en) 2011-06-23
EP1828378A2 (en) 2007-09-05
MX2007007288A (es) 2008-02-25
PL1828378T3 (pl) 2014-10-31
AU2005317304A1 (en) 2006-06-22
NO340331B1 (no) 2017-04-03
NZ555889A (en) 2009-07-31
CN101203605A (zh) 2008-06-18
BRPI0519923A2 (pt) 2009-08-11
US20080274145A1 (en) 2008-11-06
WO2006065139A2 (en) 2006-06-22
ES2493440T3 (es) 2014-09-11
NO20073088L (no) 2007-09-17
DK1828378T3 (da) 2014-09-01
PT1828378E (pt) 2014-10-10
EP1828378B1 (en) 2014-06-11
BRPI0519923A8 (pt) 2018-01-23
CA2590906C (en) 2017-01-03
US8048433B2 (en) 2011-11-01
JP2008523805A (ja) 2008-07-10

Similar Documents

Publication Publication Date Title
NO340331B1 (no) Deacylering av LPS i gramnegative bakterier
EP0649435B1 (en) Membrane-associated immunogens of mycobacteria
US20180148482A1 (en) Toxoid Peptides Derived From Phenol Soluble Modulin, Delta Toxin, Superantigens, and Fusions Thereof
WO2008156729A2 (en) Vaccines against chlamydia infection
JP2020510726A (ja) 低下した反応源性を有するｌｐｓを含むボルデテラワクチン
US20080200665A1 (en) Nucleic acid molecules encoding proteins which impart the adhesion of Neisseria cells to human cells
US20250263447A1 (en) Ompa mutations enhance omv production in bordetella pertussis
CA2378862C (en) Multi-component vaccine to protect against disease caused by haemophilus influenzae and moraxella catarrhalis
CN107823638A (zh) 一种b群脑膜炎球菌重组嵌合蛋白疫苗及其制备方法
JP6401148B2 (ja) 抗原および抗原の組み合わせ
JP2011116659A (ja) 組換え皮膚壊死トキソイドを含有する豚萎縮性鼻炎用薬剤
US6335182B1 (en) Recombinant Haemophilus influenzae adhesin proteins
JP7303791B2 (ja) スーパー抗原トキソイドに由来する融合ペプチドを含む免疫原性組成物
US6020125A (en) Basal body rod protein FlgF of campylobacter
KR101713635B1 (ko) 비브리오 패혈증균의 시스테인 단백질 분해효소 도메인 유래 재조합 단백질 및 이의 용도
JPH0723784A (ja) 百日咳ワクチン
RU2196176C2 (ru) АНАЛОГ HIN47 Haemophilus С РЕДУЦИРОВАННОЙ ПРОТЕАЗНОЙ АКТИВНОСТЬЮ
MXPA99011210A (es) Genes receptores de lactoferrina de moraxella

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: YOUWEISHENGFULIHE SPORTS

Free format text: FORMER OWNER: NV NETHERLANDS VACCINE INSTITUTE

Effective date: 20090515

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20090515

Address after: Holland Hague

Applicant after: DE STAAT DER NEDERLANDEN, VERT. DOOR DE MINISTER VAN VWS

Address before: Bill de Holland

Applicant before: Nvi Nederlands Vaccininstituut

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160127

Termination date: 20211216

CF01 Termination of patent right due to non-payment of annual fee